Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer.
We have investigated the influence of CCND1 genotype on clinical outcome in 138 women with epithelial ovarian cancer. CCND1 genotypes were identified from peripheral blood DNA by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) analysis. Patient CCND1 genotypes were compared with clinical details including FIGO tumor stage, residual tumor volume, tumor histology and differentiation, response to chemotherapy, progression free interval, and survival. We observed no association between patient CCND1 genotypes and tumor characteristics or response to chemotherapy. There was no significant difference in overall survival and progression free interval (PFI) among women with different CCND1 genotypes. However, analysis of data from patients who responded to postoperative chemotherapy revealed that women with CCND1 AA genotype were associated with early disease progression (P = 0.020, HR 4.58, 95% CI 1.27-16.48) and reduced survival (P = 0.026, HR 4.48, 95% CI 1.19-16.79) compared with those with CCND1 AG and GG genotypes. These data show that CCND1 genotype does not influence overall prognosis in a cohort of epithelial ovarian cancer patients, however, it is associated with disease progression in a subgroup of patients following initial response to chemotherapy.
Centre for Cell and Molecular Medicine, University of Keele School of Postgraduate Medicine, North Staffordshire Hospital, Stoke-on-Trent, UK;Department of Obstetrics and Gynaecology, City General, Stoke-on-Trent, UK;Department of Histopathology, North Staffordshire Hospital, Stoke-on-Trent, UK;Department of Mathematics, Keele University, Staffordshire, UK.
K. K.
KK
Dhar
K.
K
Branigan
R. E. J.
RE
Howells
C.
C
Musgrove
P. W.
PW
Jones
R. C.
RC
Strange
A. A.
AA
Fryer
C. W. E.
CW
Redman
P. R.
PR
Hoban